Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT04475939 |
| Title | Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo and Pembrolizumab as Maintenance Therapy (ZEAL-1L) |
| Acronym | ZEAL-1L |
| Recruitment | Active, not recruiting |
| Gender | both |
| Phase | Phase III |
| Variant Requirements | No |
| Sponsors | GlaxoSmithKline |
| Indications | |
| Therapies | |
| Age Groups: | adult | senior |
| Covered Countries | USA | TUR | SWE | ROU | POL | NOR | NLD | ITA | IRL | HUN | GRC | GBR | FRA | ESP | DEU | CHE | BRA | BGR | BEL | AUS | ARG |